The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders

Leukemia. 2008 Feb;22(2):450-1. doi: 10.1038/sj.leu.2404896. Epub 2007 Sep 13.

Authors

C Bellanné-Chantelot, P Jego, P Lionne-Huyghe, M Tulliez, A Najman; French group on myeloproliferative disorders

PMID: 17851561
DOI: 10.1038/sj.leu.2404896

No abstract available

Publication types

Letter

MeSH terms

Family Health
Humans
Janus Kinase 2 / genetics*
Mutation, Missense*
Myeloproliferative Disorders / etiology*
Time Factors

Substances

Janus Kinase 2